Screener Summaries Updates Institutions Sign In More Updates › Mergers & Acquisitions › BIIB Mergers & Acquisitions · May 14, 2026
Biogen has completed its acquisition of Apellis Pharmaceuticals for approximately $5.3 billion, funded in part by a… BIIB Biogen Inc.
Biogen has completed its acquisition of Apellis Pharmaceuticals for approximately $5.3 billion, funded in part by a new $2 billion term loan facility. The transaction includes contingent value rights (CVRs) that could pay up to $4.00 per share based on future SYFOVRE sales milestones. This acquisition expands Biogen's product portfolio but increases its leverage and introduces performance-linked contingent liabilities.
More from Biogen Inc. Biogen reports Q3 revenue of $2.8B, up 11%, and raises full-year Non-GAAP EPS guidance to $12.20-$13.00 Oct 28, 2026 Biogen Inc. reported second quarter 2026 financial results with total revenue of $2.7 billion, a 3% year-over-year… Jul 29, 2026 Biogen Inc. expects to incur approximately $164 million in pre-tax acquired in-process research and development… Jul 1, 2026 Biogen Inc. filed this amendment to its May 14, 2026, Form 8-K to clarify that the acquisition of Apellis… Jun 10, 2026 Biogen Inc. announced its financial results for the first quarter ended March 31, 2026, in a press release issued on… Apr 29, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
